

EBAMed Closes CHF 1.2 Million Seed Financing to Advance Non-Invasive Therapy for Heart Arrhythmias

Funding supports development of first integrated heart motion management system and pre-clinical testing

Geneva, Switzerland, August 21st, 2019 – [EBAMed SA](#), a medical technology company enabling access to non-invasive treatments for heart arrhythmias, today announced the successful completion of a CHF 1.2 million seed financing round. This first investment round was led by Fongit Seed Invest with the support of FONGIT, and includes several investors. EBAMed develops medical devices to enhance protontherapy, a precise non-invasive treatment option for heart arrhythmia patients. The seed financing will be used to test EBAMed's first integrated ultrasound-based device to monitor heart motion and command the therapy machine. These pre-clinical tests are planned for 2020 in at least one protontherapy center in Europe or the United States.

The foundational understanding on the use of protons for arrhythmia treatment is based on pre-clinical research performed by Douglas Packer, M.D. at the [Mayo Clinic](#). EBAMed is developing hardware and software that expand treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients. Mayo Clinic and Dr. Packer have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

„EBAMed's medical device provides a non-invasive method to safely perform ablation using proton beams. The latter have the physical characteristic of depositing most of their energy in the last few millimetres of their path. By adjusting the beam's position and energy, the targeted 3D volume, in this case the heart, can be precisely covered, sparing surrounding healthy tissues.“ says Giovanni Leo, Chairman of the Board and medtech industry veteran.

“Today, there are major limitations in the treatment of heart arrhythmias using invasive catheters,” said Adriano Garonna, PhD, CEO of EBAMed. “By bringing the first medical product for protontherapy of heart arrhythmias to the market, we believe we can provide medical doctors with an effective and practical method to treat more patients at an earlier stage of disease, before their quality of life has dropped significantly due to their heart arrhythmia.”

Heart arrhythmias

Heart arrhythmias are disruptions in the normal heartbeat, which affect around 15 million people in Europe and North America and are expected to at least double in the next 50 years. Surgical interventions, called ablations, are often used to treat arrhythmias and consist in burning heart tissues to stop the local conduction of the disrupted electrical signals. There are up to 600,000 ablation procedures per year, corresponding to an aggregate CHF 10+ billion market with an 8% CAGR. Apart from the patient discomfort due to the surgical procedure (under anaesthesia) and the high cost due to the length (2-7 hours) and manpower required (up to 10 medical staff), the treatment effectiveness varies largely between 20%-80%. Surveys of medical doctors indicate that the limitations are linked to the quality of the ablation lesion created by invasive ablation.

About EBAMed

EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. EBAMed is a recipient of VentureKick and Horizon 2020 funds, and was awarded Venture 2018 Best Business Plan, Mass Challenge Switzerland 2018 Platinum Prize and selected for IMD's 2018 start-up program. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. Please visit www.eba-med.com and our [Linked-In page](#).

About Mayo Clinic

[Mayo Clinic](#) is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. [Visit the Mayo Clinic News Network](#) for additional Mayo Clinic news and [An Inside Look at Mayo Clinic](#) for more information about Mayo.

About FONGIT Seed Invest

Fongit Seed Invest (FSI) is one of the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital and it actively assists entrepreneurs to foster, expand and strengthen their venture by leveraging its strong network of partners and experts. FSI acts either as a lead investor or co-investor and its linkages with venture capitalists, business angels, and institutional funds often makes it instrumental in raising additional capital in successive investment rounds.

About FONGIT

The "Fondation Genevoise pour l'Innovation Technologique" - FONGIT, is Switzerland's premier innovation incubator supporting innovative tech ventures in Geneva. Founded in 1991, Fongit has an excellent track record of building successful companies. It is a private, non-profit foundation, whose mission is to transform technology into social & economic value in the Geneva region. FONGIT benefits from the support of the State of Geneva. For more information about FONGIT, visit <https://fongit.ch>.

Company Contacts:

EBAMed:

Adriano Garonna, PhD
CEO
adriano.garonna@eba-med.com

###